The group developed a decision tool to predict survival outcomes in older AML patients using mutations in seven genes, NPM1, NRAS, KRAS, ASXL1, DNMT3A, TP53, and FLT3-ITD. This evidence concerns the gene NPM1 and acute myeloid leukemia.